Jotham W Coe

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
    Jotham W Coe
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, USA
    J Med Chem 48:3474-7. 2005
  2. ncbi In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine
    Jotham W Coe
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 15:2974-9. 2005
  3. ncbi 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation
    Jotham W Coe
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 15:4889-97. 2005
  4. ncbi A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6/4beta4 nicotinic receptor agonists
    John A Lowe
    Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, United States
    Bioorg Med Chem Lett 20:4749-52. 2010
  5. ncbi Enantioselective synthesis of nicotinic receptor probe 7,8-difluoro-1,2,3,4,5,6- hexahydro-1,5-methano-3-benzazocine
    Crystal G Bashore
    Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, Groton, Connecticut 06340, USA
    Org Lett 8:5947-50. 2006
  6. ncbi Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo eff
    Christopher J O'Donnell
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, USA
    J Med Chem 53:1222-37. 2010
  7. ncbi Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation
    Hans Rollema
    Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    Trends Pharmacol Sci 28:316-25. 2007
  8. ncbi Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect
    Hans Rollema
    Department Neuroscience, Pfizer Global Research and Development, Groton, CT 06340, USA
    Eur J Pharmacol 605:114-6. 2009
  9. ncbi Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro
    R Scott Obach
    Department of Pharmacokinetics, Dynamics, and Drug Metabolism, Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340, USA
    Drug Metab Dispos 34:121-30. 2006
  10. ncbi Twisted amide reduction under Wolff-Kishner conditions: synthesis of a benzo-1-aza-adamantane derivative
    Crystal G Bashore
    Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, Groton, CT 06340, USA
    J Am Chem Soc 125:3268-72. 2003

Collaborators

Detail Information

Publications12

  1. ncbi Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
    Jotham W Coe
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, USA
    J Med Chem 48:3474-7. 2005
    ..Varenicline displays high alpha4beta2 nAChR affinity and the desired in vivo dopaminergic profile...
  2. ncbi In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine
    Jotham W Coe
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 15:2974-9. 2005
    ..In vivo, selected compounds exhibit lower efficacy partial agonist profiles than that of (-)-cytisine...
  3. ncbi 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation
    Jotham W Coe
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 15:4889-97. 2005
    ..In vivo, selected agents demonstrate potent partial agonist efficacy on the mesolimbic dopamine system, a key measure of therapeutic potential for smoking cessation...
  4. ncbi A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6/4beta4 nicotinic receptor agonists
    John A Lowe
    Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, United States
    Bioorg Med Chem Lett 20:4749-52. 2010
    ..Compound 17a may thus be a useful tool for studying the role of alpha3beta4 and alpha6/4beta4 nicotinic receptors in CNS pharmacology...
  5. ncbi Enantioselective synthesis of nicotinic receptor probe 7,8-difluoro-1,2,3,4,5,6- hexahydro-1,5-methano-3-benzazocine
    Crystal G Bashore
    Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, Groton, Connecticut 06340, USA
    Org Lett 8:5947-50. 2006
    ..2.1]-bicyclic core, 29...
  6. ncbi Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo eff
    Christopher J O'Donnell
    Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, USA
    J Med Chem 53:1222-37. 2010
    ....
  7. ncbi Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation
    Hans Rollema
    Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    Trends Pharmacol Sci 28:316-25. 2007
    ....
  8. ncbi Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect
    Hans Rollema
    Department Neuroscience, Pfizer Global Research and Development, Groton, CT 06340, USA
    Eur J Pharmacol 605:114-6. 2009
    ..These data suggest that varenicline may have antidepressant potential and can, when combined, augment antidepressant responses of selective serotonin reuptake inhibitors...
  9. ncbi Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro
    R Scott Obach
    Department of Pharmacokinetics, Dynamics, and Drug Metabolism, Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340, USA
    Drug Metab Dispos 34:121-30. 2006
    ..The straightforward dispositional profile of varenicline should simplify its use in the clinic as an aid in smoking cessation...
  10. ncbi Twisted amide reduction under Wolff-Kishner conditions: synthesis of a benzo-1-aza-adamantane derivative
    Crystal G Bashore
    Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc, Groton, CT 06340, USA
    J Am Chem Soc 125:3268-72. 2003
    ..Wolff-Kishner conditions (KOH/ethylene glycol, 200 degrees C) provide the reduced target 1 without hydrolysis to amino acid derivatives. These operations are conveniently performed in a single flask in high yield...
  11. ncbi Varenicline: new treatment with efficacy in smoking cessation
    Victor I Reus
    Department of Psychiatry, University of California School of Medicine, San Francisco, California 94143 0984, USA
    Drugs Today (Barc) 43:65-75. 2007
    ..Its targeted mechanism of action, superior efficacy and excellent tolerability make varenicline a welcome and useful addition to the therapeutic options for smoking cessation...
  12. ncbi Structural and rate studies of the formation of substituted benzynes
    Jason C Riggs
    Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, New York 14853 1301, USA
    J Am Chem Soc 130:3406-12. 2008
    ....